Prof. Xiaojian Liu 刘晓健
Chief Physician, Professor
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of lymphoma and common solid tumors. Expertise in targeted therapy, cell therapy, CAR-T, hematopoietic stem cell transplantation, and management of chemotherapy adverse reactions.
Dr. Liu holds a PhD in Oncology from Fudan University Shanghai Medical College and a Master’s in Hematology from Suzhou Medical College. A visiting scholar at MD Anderson Cancer Center, Dr. Liu has 34 years of clinical experience, focusing on lymphoma. Roles include former assistant reviewer at the National Medical Products Administration and principal investigator for National Natural Science Foundation projects.
Professional roles
- Standing Committee Member, Integrated Traditional Chinese and Western Medicine Lymphoma Professional Committee, China Anti-Cancer Association
- Member, Clinical Research of Oncology Drugs Professional Committee, Shanghai Anti-Cancer Association
- Member, Cancer Rehabilitation and Palliative Care Professional Committee, Shanghai Anti-Cancer Association
Name order: in Chinese the family name comes first (Liu Xiaojian). Papers usually list the name as Xiaojian Liu or Liu X.
Selected publications
26 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Gene Med, 2024 (senior author): USP18 promotes colon adenocarcinoma progression via targeting the ERK-MNK signaling pathway. PubMed 38949077
- Cell Biochem Funct, 2020 (senior author): Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape. PubMed 31709594
- Hematology, 2017 (first author): A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation. PubMed 27884092
- Cancer Chemother Pharmacol, 2012 (first author): Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study. PubMed 21789688
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion